In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.